Read Article:
https://sourcebioscience.com/what-are-the-four-steps-of-next-gen-sequen…
With the new Labour government pledging to 'build an NHS fit for the future', an injection of money, whilst welcome, will not be enough - it must be rolled out in a measured and integrated way that works more closely with the private sector in order to make a real difference, says RSM UK.
Clive Makombera, partner and head of NHS at the leading audit, tax and consulting firm RSM UK, comments: 'Labour’s plans for the NHS imply seismic changes in workforce performance and culture. The government has set itself the challenge of clearing waiting times for elective treatment of…
Read July's eNews here
Featuring:
Tony Jones intro following ON Helix 2024
Simple Steps for a Greener Life Sciences Lab
The Evolving Life Sciences Landscape
Deal-making for Cell and Gene Therapy Companies: Insights from One Nucleus’ Panel Event
A Truly Golden Triangle for Life Sciences
Building the Right Environment for Life Science Companies
Beyond Borders: EY Biotechnology Report 2024
Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024
Cambridge, UK – 9 July 2024: Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines called live biotherapeutic products (LBPs), announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA,…
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth. Additional new investors British Patient Capital (a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank), Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon…
New R&D rules around contracted-out R&D are set to impact Clinical Research Organisations (CROs). Lizzie Gosling, innovations reliefs specialist for the life sciences and healthcare sector, looks at the key R&D regime changes and why CROs’ contracts need to be put under the spotlight.
What are the key changes?
The merger of the RDEC (‘R&D Expenditure Credit’) and SME (‘Small and Medium Enterprise’) R&D regimes comes into effect for periods starting on or after 1 April 2024. The goal of this merger is to offer a more streamlined and…
The NHS’ Health Research Authority (HRA) recently published its draft template Investigator Initiated Study Agreement (IIS Agreement)1 and called for comments on the draft.
According to the HRA, and in a similar way to the other model agreements used for other types of clinical trials conducted in the UK, the IIS Agreement is intended to act as a “standard contract agreement template” for use between non-commercial sponsors and commercial organisations providing support for investigator-initiated studies.
In principle, this is good news for the UK life sciences…
Cambridge, 27th June 2024: Leading regional property investor and developer Howard Group, is delighted to have been awarded ‘Commercial Project of the Year’ for its flagship science and technology hub, Unity Campus, at the Eastern Echo Awards on Wednesday 26th June.
Held at Homerton College, Cambridge and now in its third year, the well-respected Eastern Echo Awards showcase and celebrate the best of the East of England’s property industry. Unity Campus was shortlisted in three categories - ‘Commercial Project of the Year’, ‘Deal of the year’ (submitted by Mills Reeve for the…
Key appointment to support continued UK and US team expansion
Cambridge, UK, 27 June 2024: CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced the appointment of Lydia Seymour as Vice President of People and Culture. In this role, Lydia will work alongside the Company’s management team, providing guidance and support across recruitment and employee wellbeing, in addition to ensuring the implementation of robust professional development plans for CN Bio’s growing global team, and driving new initiatives to enhance workplace culture.
Lydia’s…
AMSBIO has launched a Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line.
GLP-1R is known to play a key role in controlling blood sugar levels by enhancing glucose-stimulated insulin secretion. Therefore, there is considerable interest in harnessing regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to type 2 diabetes which has already resulted in the development of several GLP-1 FDA-approved agonists. In addition, GLP-1R agonists have also been shown to contribute to weight management, decrease the potential for cardiovascular diseases and…